All type of patients: 3 trials - BOLERO-2 - TAMRAD - BOLERO-3
| everolimus + exemestane vs exemestane alone | progression or death (progression free survival PFS) by 57% (fully demonstrated) | |
| everolimus + tamoxifen vs tamoxifen alone | No demonstrated result suggested progression (Time to progression TTP) by 46% (not demonstrated) suggested death (overall survival) by 55% (not demonstrated) | |
| everolimus + trastuzumab + vinorelbine vs trastuzumab + vinorelbine alone | progression or death (progression free survival PFS) by 22% (fully demonstrated) |
All type of patients: 2 trials - RECORD-1 - RECORD 3
| everolimus vs placebo | No demonstrated result suggested progression or death (progression free survival PFS) by 70% (not demonstrated) | |
| everolimus vs sunitinib | No demonstrated result suggested progression or death (progression free survival PFS) by 40% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
